TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
By organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million in Q4 2025
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceTotal revenue for Q4 was approximately $161 million with U.S. transplant revenue of approximately $155 million, up 33% year-over-year and 11% sequentially
80% confidenceQ4 2025 total revenue was approximately $161 million, with U.S. transplant revenue of approximately $155 million, up 33% year-over-year and 11% sequentially
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceThe makers of styrofoam box competitor are refusing to randomize their technology against OCS in ENHANCE Part B
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidence2026 operating margins expected to be up to approximately 250 basis points below 2025 full year levels, primarily reflecting timing and scale of investments
80% confidenceAlmost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% year-over-year growth and approximately 12% sequential growth
80% confidenceTotal revenue for Q4 was approximately $161 million with U.S. transplant revenue at approximately $155 million, up 33% year-over-year and 11% sequentially
80% confidenceThe makers of the styrofoam box technology are refusing to randomize their technology against TransMedics in ENHANCE Part B trial
80% confidenceTransMedics achieved its best operational performance to date in Q4 2025 despite external challenges designed to distract and disrupt growth
80% confidenceMost lung centers were waiting to see FDA approval before launching into DENOVO program
80% confidenceLiver market share gains are pure TransMedics execution excellence, period, full stop
80% confidenceUpcoming registry publication will demonstrate unequivocal statistical superiority in the most important outcomes after liver transplantation
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue for fourth quarter while making substantial investments to fuel growth
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceLiver market share gains represent pure TransMedics execution excellence
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceOperating margins expected to approach 30% by 2028
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceOCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceOperating profit of approximately $21.3 million in Q4 represented approximately 13.2% of total revenue
80% confidenceNOP Connect 2.0 is showing efficiency in management and billing, though in early stages
80% confidenceAlmost 50% of the incremental investment in 2026 is driven by really 3 elements and those, by nature, are transitory
80% confidenceTransMedics is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceTransMedics was prepared and expected ENHANCE Part B trial challenges, and will execute Part B hoping for significant success
80% confidence